By analyzing circulating cell-free DNA profiling, we determined that cfDNA/ctDNA profiling is a novel biomarker to predict the prognosis of u-HCC patients treated with anti-PD-L1 and anti-VEGF combination immunotherapy. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.